|
Apr 11
|
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs
|
|
Apr 10
|
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025
|
|
Apr 10
|
PatientView Ranks Gilead "Best" at ESG
|
|
Apr 9
|
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
|
|
Apr 9
|
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
|
|
Apr 9
|
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
|
|
Apr 9
|
2 Top Dividend Stocks That Could Set You Up for Life
|
|
Apr 8
|
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections
|
|
Apr 7
|
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
|
|
Feb 26
|
The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant
|
|
Feb 26
|
Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
|
|
Feb 25
|
Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic
|
|
Feb 25
|
Morgan Stanley sees FDA approval of GILD's Lenacapavir
|
|
Feb 25
|
4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty
|
|
Feb 25
|
Gilead’s lenacapavir applications for HIV gain EMA validation
|
|
Feb 24
|
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
|
|
Feb 23
|
Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks
|
|
Feb 21
|
Gilead’s lenacapavir under priority review could revolutionise HIV PrEP
|
|
Feb 21
|
Some Investors May Be Willing To Look Past Gilead Sciences' (NASDAQ:GILD) Soft Earnings
|
|
Feb 20
|
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
|